Abstract:Therapeutic agents that improve the memory loss of AD may be developed if drug targets are identified in appropriate AD animal models. One such target is beta-secretase which, in most AD patients, cleaves the wild-type (WT) beta-secretase site sequence of APP to produce neurotoxic beta-amyloid (Abeta). Therefore, an animal model representing most AD patients for evaluating beta-secretase is one that expresses the WT beta-secretase site sequence of APP. The aspartyl protease BACE1 and cysteine protease cathepsin B (CatB) have beta-secretase activity, but gene knockout studies have not yet validated that the absence of these proteases improves memory deficits in such an animal model. This study assessed the effects of deleting these protease genes on memory deficits in the AD mouse model expressing human APP containing the WT beta-secretase site sequence and the London gamma-secretase site (APPWT/Lon mice), as well as the effects of administering the cysteine protease inhibitor E64d on memory deficits in that model. Firstly, transgenic APPWT/Lon mice with deletion of the cathepsin B or BACE1 gene were generated. Secondly, APPWT/Lon mice were treated with E64d by oral administration. Both gene deletion and E64d treated animals were assessed for memory deficits by the Morris water maze test, for brain amyloid plaques by immunohistophathology, and for brain Abeta peptides and APP-derived fragments by ELISA and western analyses. Knockout of the CatB gene in the APPWT/Lon mice improved memory deficits and altered the pattern of Abeta-related biomarkers in a manner consistent with CatB having WT beta-secretase activity. But deletion of the BACE1 gene had no effect on these parameters in the APPWT/Lon mice. These data are the first to show that knockout of a putative beta-secretase gene results in improved memory in an AD animal model expressing the WT beta-secretase site sequence of APP, present in the majority of AD patients. Furthermore, treatment of these mice with E64d, by oral administration, resulted in improved memory deficits and reduced brain Abeta. CatB may be an effective drug target and E64d may be an effective oral therapeutic agent for improving memory deficits in the majority of AD patients.

BACE1 RNA interference improves spatial memory and attenuates Aβ burden in a streptozotocin-induced tau hyperphosphorylated rat model.

A butyrolactone derivative 3BDO alleviates memory deficits and reduces amyloid-β deposition in an AβPP/PS1 transgenic mouse model.

The BACE1-Specific DNA Aptamer A1 Rescues Amyloid-β Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

The Effect of BACE1-AS on Β-Amyloid Generation by Regulating BACE1 Mrna Expression

Astrocytic AT1R deficiency ameliorates Aβ-induced cognitive deficits and synaptotoxicity through β-arrestin2 signaling

Targeted BACE-1 inhibition in microglia enhances amyloid clearance and improved cognitive performance

BACE1 Aptamer-Modified Tetrahedral Framework Nucleic Acid to Treat Alzheimer's Disease in an APP-PS1 Animal Model

Inhibition of Sphingomyelin Synthase 1 Ameliorates Alzheimer-Like Pathology in APP/PS1 Transgenic Mice Through Promoting Lysosomal Degradation of BACE1

A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment

BACE1 controls synaptic function through modulating release of synaptic vesicles

P2‐359: Cathepsin B Gene Deletion or Inhibition Improves Memory Deficits in a Mouse Model of Alzheimer's Disease Expressing APP with the Wild‐type Beta‐secretase Site

Knockdown of BACE1 by a multistage brain-targeting polyion complex improved memory and learning behaviors in APP/PS1 transgenic mouse model

Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease

BACE1 SUMOylation Increases Its Stability and Escalates the Protease Activity in Alzheimer's Disease.

Dicer1 promotes Aβ clearance via blocking B2 RNA-mediated repression of apolipoprotein E

Beta Secretase Localization, Amyloid Deposition And Aberrant Synaptic And Neuritic Sprouting In Transgenic Mouse Alzheimer Models: A Role For Bace1 In Synaptic Remodeling And Plaque Formation?

BAY 73-6691 Alters Neuron Plasticity and Phosphorylation of Tau Through Regulation of Cyclic Guanosine Monophosphate/Protein Kinase G/Cyclic Adenosine Monophosphate Response Element-Binding Protein Pathway

β-Secretase 1’s Targeting Reduces Hyperphosphorilated Tau, Implying Autophagy Actors in 3xTg-AD Mice

RTN4B‐mediated suppression of Sirtuin 2 activity ameliorates β‐amyloid pathology and cognitive impairment in Alzheimer's disease mouse model

O4‐02‐01: A Novel Role of Beta‐secretase1 (BACE1) in the Pathogenesis of Cerebral Amyloid Angiopathy (CAA)